An Observational Multi-Center Study Exploring the Association of Safety, Patient Characteristics, Virological, and Histological Parameters With Patient Outcome (Relapse Rate, Achievement of Sustained Viral Response in Daily Clinical Practice in Belgium- PEGIMPACT

Trial Profile

An Observational Multi-Center Study Exploring the Association of Safety, Patient Characteristics, Virological, and Histological Parameters With Patient Outcome (Relapse Rate, Achievement of Sustained Viral Response in Daily Clinical Practice in Belgium- PEGIMPACT

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2014

At a glance

  • Drugs Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Acronyms PEGIMPACT
  • Sponsors Merck & Co; Schering-Plough
  • Most Recent Events

    • 03 Mar 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 12 Nov 2008 Planned initiation date changed from 1 Sep 2008 to 1 Jan 2009.
    • 21 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top